Nephrocare Health Services Limited – Investor Presentation Summary
Key Operational Highlights
- Guests served increased 13.0% YoY to 38,262 in Q1FY27 (Q1FY26: 33,868)
- Treatments performed grew 13.3% YoY to 10,31,084 (Q1FY26: 9,09,860)
- Revenue per treatment improved 9.2% YoY to ₹2,733 (Q1FY26: ₹2,503)
- Network expanded to 550+ operating clinics across 350+ cities in 5 countries
- Added 7 clinics in the Philippines during Q1FY27, taking total to 51 clinics
- Uzbekistan operations serve 1,400+ guests across 6 clinics in 3 provinces
- Saudi Arabia operations commenced home dialysis treatments and obtained medical operator license
Key drivers of operational performance: Steady volume growth, geographic expansion into international markets, and improved revenue per treatment.
Segment-wise Performance
Not Specified
Financial Highlights
Revenue: ₹281.8 crore
EBITDA: ₹63.9 crore (Adjusted EBITDA: ₹65.1 crore)
PAT: ₹32.0 crore (Adjusted PAT: ₹36.8 crore)
EPS: Not Specified
Margins: EBITDA Margin 22.7%, Adjusted EBITDA Margin 23.1%, Adjusted PAT Margin 13.1%
YoY comparison: Revenue up 23.7%, Adjusted EBITDA up 30.7%, Adjusted PAT up 41.7%
QoQ comparison: Revenue up 6.1%, Adjusted EBITDA up 17.5%, Adjusted PAT up 4.7%
Drivers of financial performance: Volume growth with treatments up 13.3% YoY, improved revenue per treatment up 9.2% YoY, and operating leverage benefits.
Comparison to market estimates: Not Specified
Key Risks: Not explicitly disclosed in presentation
Geographical Revenue Split
Domestic vs Export/Regional Revenue: Not Specified
Balance Sheet Snapshot
Net Debt/Equity: Not Specified
Reserves: Not Specified
Current Assets/Liabilities: Not Specified
Working Capital/Leverage Metrics: Not Specified
Financial Health Insights: Strong cash flow generation with operating profit before working capital changes of ₹265.7 crore in FY26
Capex & Cash Flow Health
Capital Expenditure: Not Specified for current period
Free Cash Flow: Not Specified
Operating Cash Flow: Net cash from operating activities was ₹232.6 crore in FY26
Net Debt Movement: Not Specified
Investment Rationale: Focus on international expansion through strategic acquisitions and partnerships
Strategic & R&D Initiatives
Investments in Innovation: Launched NephroPlus International Dialysis Academy (NIDA) for renal nurse training, developed NephroPlus Dialysis Index for clinical outcome monitoring, initiatives to increase fistula creation and reduce cross-infections
Expected impact on growth: Training academy to enable efficient staffing of international clinics where hiring renal nurses is challenging
Strategic Rationale: Expanding into high-growth international markets while maintaining cost discipline from Indian operations
Industry Trends & Business Environment
Macro/Industry Trends: Dialysis market growing due to increasing burden of Diabetes and Hypertension, shift from unorganized to organized dialysis in India (only 21% served by organized networks currently)
Impact on Company: NephroPlus as market leader in India stands to gain disproportionately from industry shift to organized care
Management Commentary & Growth Outlook
Strategic Outlook: "Dialysis services across the World are mostly delivered by Pure play dialysis networks. In India, today, only 21% of the dialysis services market is served by Pure play dialysis networks. 16 years ago, this number was zero. As the dialysis industry is shifting from Unorganized to Organized, NephroPlus, as the market leader in India stands to gain disproportionately due to its focus on clinical quality, service excellence and patient centricity."
FY Guidance: Not explicitly provided
Market Share Targets: 50%+ market share in Indian organized dialysis market
Risks and Opportunities: Exploring entry into new countries via strategic acquisitions or long-term partnerships with payors
ESG Updates
Impact Metrics: 550 centers, 38,262 guests served, 68.6% male and 31.3% female guests, 76.5% patients using public insurance
ESG Metrics: 4,458 people trained, 1,828 females trained, 8,018 total training hours in Q1FY27